+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Friedreich Ataxia - Pipeline Insight, 2025 - Product Thumbnail Image

Friedreich Ataxia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Encephalopathy- Pipeline Insight, 2025 - Product Thumbnail Image

Encephalopathy- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 210 Pages
  • Global
From
Tourette Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Tourette Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Autism - Pipeline Insight, 2025 - Product Thumbnail Image

Autism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Traumatic Brain Injury(TBI) - Pipeline Insight, 2025 - Product Thumbnail Image

Traumatic Brain Injury(TBI) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Ataxia - Pipeline Insight, 2025 - Product Thumbnail Image

Ataxia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Serotonin 1B Receptor Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

Serotonin 1B Receptor Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Histamine H1 Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Histamine H1 Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
T Type Calcium Channel Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

T Type Calcium Channel Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Alzheimer's Disease (AD) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Alzheimer's Disease (AD) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 157 Pages
  • Global
From
Cervical Dystonia - Epidemiology Forecast - 2034 - Product Thumbnail Image

Cervical Dystonia - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 75 Pages
  • Global
From
Myotonic Dystrophy - Epidemiology Forecast - 2034 - Product Thumbnail Image

Myotonic Dystrophy - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 105 Pages
  • Global
From
Mild Cognitive Impairment - Epidemiology Forecast - 2034 - Product Thumbnail Image

Mild Cognitive Impairment - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 106 Pages
  • Global
From
Amyotrophic Lateral Sclerosis (ALS) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis (ALS) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 133 Pages
  • Global
From
Parkinson's Disease - Epidemiology Forecast - 2034 - Product Thumbnail Image

Parkinson's Disease - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 159 Pages
  • Global
From
Myasthenia Gravis - Epidemiology Forecast - 2034 - Product Thumbnail Image

Myasthenia Gravis - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 143 Pages
  • Global
From
From
From
Etanercept - Biosimilar Insight, 2024 - Product Thumbnail Image

Etanercept - Biosimilar Insight, 2024

  • Report
  • August 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more